NextCure (NXTC) Amortizatization of Intangibles (2021 - 2026)
NextCure (NXTC) posted quarterly Amortizatization of Intangibles of $59000.0 for Q1 2026, down 75.11% year-over-year from $237000.0 in Q1 2025, and up 20.41% quarter-over-quarter from $49000.0 in Q4 2025.
NextCure (NXTC) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
NextCure's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $59000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 75.11% year-over-year to $59000.0; the TTM figure through Mar 2026 stood at $303000.0 (down 73.95% YoY), while the FY2025 annual figure was $481000.0, down 60.89% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $59000.0, up from $49000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $333000.0 in Q3 2024, with the low at -$1.0 million in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $149000.0 (2025), against an average of -$30647.1.
- The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles plunged 94.35% in 2022, then jumped 470.73% in 2024.
- NextCure's Amortizatization of Intangibles stood at -$453000.0 in 2022, then jumped by 171.52% to $324000.0 in 2023, then decreased by 12.65% to $283000.0 in 2024, then slumped by 82.69% to $49000.0 in 2025, then advanced by 20.41% to $59000.0 in 2026.
- Business Quant data shows NXTC's Amortizatization of Intangibles at $59000.0 in Q1 2026, $49000.0 in Q4 2025, and $46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41,000.00 |
| Jun 30, 2026 | 41,000.00 |
| Mar 31, 2026 | 59,000.00 |
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Dec 31, 2025 | 49,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Mar 31, 2025 | 237,000.00 |
| Mar 31, 2025 | 237,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 310,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Mar 31, 2024 | 304,000.00 |